Oral Ixazomib, lenalidomide, and dexamethasone for multiple myeloma

New England Journal of Medicine

Volumn 374, Issue 17, 2016, Pages 1621-1634

  Moreau, P ^a   Masszi, T ^d   Grzasko, N ^e   Bahlis, N J ^f   Hansson, M ^h   Pour, L ⁱ   Sandhu, I ^g   Ganly, P ^j   Baker, B W ^k   Jackson, S R ^l   Stoppa, A M ^b   Simpson, D R ^m   Gimsing, P ⁿ   Palumbo, A ^o   Garderet, L ^c   Cavo, M ^p   Kumar, S ^q   Touzeau, C ^a   Buadi, F K ^q   Laubach, J P ^r   Berg, D T ^s   Lin, J ^s   Di Bacco, A ^s   Hui, A M ^s   Van De Velde, H ^s   Richardson, P G ^r   Kupperman, Eric ^t   Berger, Allison ^t   Dick, Larry ^t   Williamson, Mark ^t   Chauhan, Dharminder ^t   Anderson, Kenneth ^t   Esseltine, Dixie Lee ^t   Niculescu, Liviu ^t   Taraskiewicz, Stacey ^t   Stecklair, Jeff ^t   Lonial, Sagar ^t   Rajkumar, Vincent ^t   Miquel, Jésus San ^t   Einsele, Hermann ^t   Orlowski, Robert ^t   more..

^a HÔTEL DIEU   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c HÔPITAL SAINT ANTOINE   (France)

^d SEMMELWEIS UNIVERSITY   (Hungary)

^e MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^j CHRISTCHURCH HOSPITAL   (New Zealand)

^k PALMERSTON NORTH HOSPITAL   (New Zealand)

^l MIDDLEMORE HOSPITAL   (New Zealand)

^m NORTH SHORE HOSPITAL   (New Zealand)

ⁿ Rigshospitalet   (Denmark)

^o UNIVERSITY OF TURIN   (Italy)

^p UNIVERSITY OF BOLOGNA   (Italy)

^q MAYO CLINIC   (United States)

^r DANA FARBER CANCER INSTITUTE   (United States)

^s MILLENNIUM PHARMACEUTICALS INC   (United States)

^t NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; IXAZOMIB; LENALIDOMIDE; PLACEBO; ANTINEOPLASTIC AGENT; BORON DERIVATIVE; GLYCINE; THALIDOMIDE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; BACKACHE; BRAIN DISEASE; CANCER RECURRENCE; CANCER STAGING; CONSTIPATION; CONTROLLED STUDY; CREATININE CLEARANCE; CYTOGENETICS; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOTENSION; INSOMNIA; INTERSTITIAL LUNG DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE MYELOMA; MUSCLE SPASM; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; REFRACTORY MULTIPLE MYELOMA; RHINOPHARYNGITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORON COMPOUNDS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; EXANTHEMA; GLYCINE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; THALIDOMIDE; THROMBOCYTOPENIA;

EID: 84964931441     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1516282     Document Type: Article

References (34)

1. Anderson KC. Oncogenomics to target myeloma in the bone marrow microenvironment. Clin Cancer Res 2011; 17: 1225-33.
2. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28: 1122-8.
3. Röllig C, Knop S, Bornhäuser M. Multiple myeloma. Lancet 2015; 385: 2197-208.
4. Rosiñol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood 2012; 120: 1589-96.
5. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010; 376: 2075-85.
6. Durie B, Hoering A, Rajkumar SV, et al. Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT): results of the randomized phase III trial SWOG S0777. Blood 2015; 126: 25. abstract (https://ash.confex.com/ash/2015/webprogram/Paper79014.html).
7. Garderet L, Iacobelli S, Moreau P, et al. Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomized Phase III Trial from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2012; 30: 2475-82.
8. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372: 142-52.
9. Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366: 1759-69.
10. Kupperman E, Lee EC, Cao Y, et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010; 70: 1970-80.
11. Lee EC, Fitzgerald M, Bannerman B, et al. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. Clin Cancer Res 2011; 17: 7313-23.
12. Chauhan D, Tian Z, Zhou B, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011; 17: 5311-21.
13. Kumar S, Berdeja JG, Niesvizky R, et al. Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomib-lenalidomide-dexamethasone induction in patients (pts) with previously untreated multiple myeloma (MM): phase 2 study results. Blood 2014; 124: 82. abstract (https://ash.confex.com/ash/2014/webprogram/Paper69951.html).
14. Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. Lancet Oncol 2014; 15: 1503-12.
15. Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 117(18): 4691-5.
16. Lan KKG, Demets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-63.
17. Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 2014; 371: 906-17.
18. Kumar SK, Bensinger WI, Zimmerman TM, et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. Blood 2014; 124: 1047-55.
19. Richardson PG, Baz R, Wang M, et al. Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. Blood 2014; 124: 1038-46.
20. Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia 2012; 26: 595-608.
21. Millennium Pharmaceuticals. NINLARO (ixazomib) capsules, for oral use: prescribing information. November 2015 (http://www.ninlaro.com/downloads/prescribing-information.pdf).
22. Avet-Loiseau H, Hulin C, Benboubker L, et al. Impact of cytogenetics on outcomes of transplant-ineligible patients with newly diagnosed multiple myeloma treated with continuous lenalidomide plus low-dose dexamethasone in the first (MM-020) trial. Blood 2015; 126: 730. abstract (https://ash.confex.com/ash/2015/webprogram/Paper81093.html).
23. Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014; 28: 269-77.
24. Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 2015; 373: 621-31.
25. Ross FM, Avet-Loiseau H, Ameye G, et al. Report from the European Myeloma Network on interphase FISH in multiple myeloma and related disorders. Haematologica 2012; 97: 1272-7.
26. Palumbo A, Bringhen S, Larocca A, et al. Bortezomib-melphalan-prednisonethalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol 2014; 32: 634-40.
27. Lonial S, Mitsiades CS, Richardson PG. Treatment options for relapsed and refractory multiple myeloma. Clin Cancer Res 2011; 17: 1264-77.
28. Center for Drug Evaluation and Research. Guidance for industry: patientreported outcome measures: use in medical product development to support labeling claims. Silver Spring, MD: Food and Drug Administration, December 2009 (http://www.fda.gov/downloads/Drugs/./Guidances/UCM193282.pdf).
29. Osborne TR, Ramsenthaler C, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ. What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools. Eur J Haematol 2012; 89: 437-57.
30. Osborne TR, Ramsenthaler C, de Wolf-Linder S, et al. Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life. BMC Cancer 2014; 14: 496.
31. Lonial S, Waller EK, Richardson PG, et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106: 3777-84.
32. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013; 98: 1753-61.
33. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011; 12: 431-40.
34. Laubach J, Garderet L, Mahindra A, et al. Management of relapsed multiple myeloma: recommendations of the international myeloma working group. Leukemia 2015 December 29 (Epub ahead of print).